Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Patients with histologically or cytologically documented acute myelogenous leukemia appropriate for cytarabine therapy including:
Arm A: Patients who have not received prior standard induction chemotherapy, considered unsuitable for standard induction therapy
Arm B: Patients who have failed their 1st or greater line of standard induction chemotherapy (primary refractory) or patients who originally achieved a complete response but are currently in first or greater relapse
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
All non-hematological adverse events of any prior chemotherapy, surgery, or radiotherapy must have resolved to NCI-CTC AE Grade \</=2
Adequate hepatic and renal function
Patient must be willing to submit the blood sampling and bone marrow sampling for PK and PD analyses and exploratory biomarkers
You may not be if
History of allergic or toxic reactions attributed to cytarabine or a history of allergic reactions to components of the formulated product
Current evidence of CNS leukemia
Any severe and/or uncontrolled medical condition or other conditions that could affect the participation in the study